Last reviewed · How we verify
Salagen
Salagen is a Small molecule drug developed by Alberta Health services. It is currently FDA-approved for Aptyalism, Ocular hypertension, Open-angle glaucoma.
Salagen, also known as Pilocarpine, is a small molecule medication used to treat dry mouth and manage conditions such as angle closure glaucoma, ocular hypertension, and primary open angle glaucoma. It is administered as eye drops to reduce pressure inside the eye and constrict the pupil after dilation.
At a glance
| Generic name | Salagen |
|---|---|
| Sponsor | Alberta Health services |
| Target | Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Aptyalism
- Ocular hypertension
- Open-angle glaucoma
- Primary Closed Angle Glaucoma
- Xerostomia Secondary to Radiation Therapy
- Xerostomia Secondary to Sjogren's Syndrome
Common side effects
- Sweating
- Urinary frequency
- Chills
- Vasodilatation (flushing)
- Nausea
- Diarrhea
- Dizziness
- Abnormal vision
- Conjunctivitis
- Dysphagia
- Epistaxis
- Myalgias
Serious adverse events
- Myocardial infarction
- Syncope
- Glaucoma
- Esophagitis
- Leukopenia
- Bradycardia
- Stridor
- Death
- Chest pain
- Neck rigidity
Key clinical trials
- Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia (PHASE3)
- Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function (NA)
- Pilocarpine Use After Kahook Goniotomy (PHASE3)
- Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia (PHASE2)
- Optimal Treatment Protocol for Selective Laser Trabeculoplasty (NA)
- Optimal Treatment Protocol for Selective Laser Trabeculoplasty - Repeat Trial (NA)
- Evaluation of NV701 (Pilocarpine 1.25%) Compared With Vuity (Pilocarpine 1.25%) on Pupil Size in Subjects With Presbyopia (EARLY_PHASE1)
- Quality of Life in Presbyopic Patients Who Are Treated With Qlosi (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salagen CI brief — competitive landscape report
- Salagen updates RSS · CI watch RSS
- Alberta Health services portfolio CI
Frequently asked questions about Salagen
What is Salagen?
What is Salagen used for?
Who makes Salagen?
What development phase is Salagen in?
What are the side effects of Salagen?
What does Salagen target?
Related
- Target: All drugs targeting Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
- Manufacturer: Alberta Health services — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Aptyalism
- Indication: Drugs for Ocular hypertension
- Indication: Drugs for Open-angle glaucoma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing